Jostein Dahle

Jostein Dahle

Company: Nordic Nanovector

Job title: Chief Scientific Officer

Seminars:

Live Discussion & Question Time 12:00 pm

Read more

day: Track A - Day 1 AM

Targeting CD37 with Alpha- & Beta-Emitting Radioimmunoconjugates 11:40 am

Review CD37 as target for radioimmunotherapy Analyse preclinical and clinical data for treatment of non-Hodgkin lymphoma with the beta-emitting radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin®) Evaluate preclinical data for treatment of chronic lymphocytic leukaemia and non-Hodgkin lymphoma with the alpha emitting radioimmunoconjugate 212Pb-TCMCNNV003 (Alpha37)Read more

day: Track A - Day 1 AM

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.